Table 1.
Patient and clinicopatholgic characteristics
| Patient demographics | Total n(%) | HPV status, n(%) | p16 status, n(%) | ||||
|---|---|---|---|---|---|---|---|
| Positive | Negative | p | Positive | Negative | p | ||
| Age (Y, median) | <0.001 | <0.001 | |||||
| ≥70Y | 70 | 56 | 65 | 57 | 68 | ||
| Range | 43-80 | 43-77 | 43-80 | 43-77 | 48-80 | ||
| Gender | 0.135 | 0.147 | |||||
| Male | 69 (93) | 18 (86) | 51 (96) | 31 (89) | 38 (97) | ||
| Female | 5 (7) | 3 (14) | 2 (4) | 4 (11) | 1 (3) | ||
| Alcohol | 0.366 | 0.292 | |||||
| Never/ social | 56 (76) | 17 (81) | 39 (74) | 28 (80) | 28 (72) | ||
| Heavy | 18 (24) | 4 (19) | 14 (26) | 7 (20) | 11 (28) | ||
| Anatomic site | 0.376 | 0.692 | |||||
| Tonsil | 47 (64) | 15 (71) | 32 (60) | 24 (69) | 23 (59) | ||
| Soft palate | 10 (13) | 1 (5) | 9 (17) | 4 (11) | 6 (15) | ||
| Tongue base | 17 (23) | 5 (24) | 12 (23) | 7 (20) | 10 (26) | ||
| Clinical stage | 0.366 | 0.502 | |||||
| III | 18 (24) | 4 (24) | 14 (26) | 9 (26) | 9 (23) | ||
| IV | 56 (76) | 56 (76) | 39 (74) | 26 (74) | 30 (77) | ||
| T stage | 0.181 | 0.062 | |||||
| T1-2 | 45 (61) | 15 (71) | 30 (57) | 25 (71) | 20 (51) | ||
| T3-4 | 29 (39) | 6 (29) | 23 (43) | 10 (29) | 19 (49) | ||
| N stage | 0.305 | 0.601 | |||||
| N0-1 | 19 (26) | 4 (19) | 15 (28) | 9 (26) | 10 (26) | ||
| N2-3 | 55 (74) | 17 (81) | 38 (72) | 26 (74) | 29 (74) | ||
| Differentiation | 0.346 | 0.099 | |||||
| Well | 23 (31) | 4 (19) | 19 (36) | 14 (40) | 10 (26) | ||
| Moderate | 19 (26) | 6 (29) | 13 (25) | 6 (17) | 17 (44) | ||
| Poorly | 8 (11) | 4 (19) | 4 (8) | 10 (29) | 9 (23) | ||
| NA | 24 (32) | 7 (33) | 17 (32) | 5 (14) | 3 (7) | ||
| PS | 0.007 | 0.001 | |||||
| 0 | 42 (57) | 17 (81) | 25 (47) | 27 (77) | 15 (38) | ||
| 1 | 32 (43) | 4 (19) | 28 (53) | 8 (23) | 24 (62) | ||
| HPV | <0.001 | ||||||
| Positive | 21 (28) | 21 (100) | 0 | 21 (60) | 0 | ||
| Negative | 53 (72) | 0 | 53 (100) | 14 (40) | 39 (100) | ||
| p16 | <0.001 | ||||||
| Positive | 35 (47) | 21 (100) | 0 | 35 (100) | 0 | ||
| Negative | 39 (53) | 0 | 0 | 0 | 39 (100) | ||
| Induction response | 0.436 | 0.018 | |||||
| CR | 22 (30) | 7 (33) | 15 (28) | 15 (43) | 7 (18) | ||
| Non-CR | 52 (70) | 14 (67) | 38 (72) | 20 (57) | 32 (82) | ||
| RT dose (cGy) | 0.429 | 0.470 | |||||
| ≥6,500 | 43 (58) | 6 (67) | 37 (57) | 21 (60) | 22 (56) | ||
| <6,500 | 31 (42) | 3 (34) | 28 (43) | 14 (40) | 17 (44) | ||
| RT type | 0.070 | 0.289 | |||||
| 3D-RT | 52 (80) | 5 (56) | 47 (84) | 25 (76) | 27 (84) | ||
| IMRT | 13 (20) | 4 (44) | 9 (16) | 8 (24) | 5 (16) | ||
| Treatment duration | 0.501 | 0.092 | |||||
| <4 months | 29 (39) | 3 (33) | 26 (40) | 17 (49) | 12 (31) | ||
| ≥4 months | 45 (61) | 6 (67) | 39 (60) | 18 (51) | 27 (69) | ||
Abbreviation: CR, complete response.